Efficacy of HER2-Targeted Intraperitoneal 225 Ac α-Pretargeted Radioimmunotherapy for Small-Volume Ovarian Peritoneal Carcinomatosis.

Autor:	Chung SK; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Vargas DB; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Chandler CS; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Katugampola S; Division of Radiation Research, Department of Radiology and Center for Cell Signaling, New Jersey Medical School, Rutgers University, Newark, New Jersey., Veach DR; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Radiology, Weill Cornell Medicine, New York, New York., McDevitt MR; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Radiology, Weill Cornell Medicine, New York, New York., Seo SH; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Vaughn BA; Department of Radiology, Weill Cornell Medicine, New York, New York.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Rinne SS; Department of Radiology, Weill Cornell Medicine, New York, New York.; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Punzalan B; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Patel M; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York., Xu H; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Guo HF; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York., Zanzonico PB; Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York., Monette S; Laboratory of Comparative Pathology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, and Rockefeller University, New York, New York; and., Yang G; Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York., Ouerfelli O; Organic Synthesis Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York., Nash GM; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Cercek A; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York., Fung EK; Department of Radiology, Weill Cornell Medicine, New York, New York., Howell RW; Division of Radiation Research, Department of Radiology and Center for Cell Signaling, New Jersey Medical School, Rutgers University, Newark, New Jersey., Larson SM; Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.; Department of Radiology, Weill Cornell Medicine, New York, New York.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Cheal SM; Department of Radiology, Weill Cornell Medicine, New York, New York; smc4002@med.cornell.edu.; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York., Cheung NV; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York.
Jazyk:	angličtina
Zdroj:	Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2023 Sep; Vol. 64 (9), pp. 1439-1445. Date of Electronic Publication: 2023 Jun 22.
DOI:	10.2967/jnumed.122.265095
Abstrakt:	Epithelial ovarian cancer (EOC) is often asymptomatic and presents clinically in an advanced stage as widespread peritoneal microscopic disease that is generally considered to be surgically incurable. Targeted α-therapy with the α-particle-emitting radionuclide 225 Ac (half-life, 9.92 d) is a high-linear-energy-transfer treatment approach effective for small-volume disease and even single cells. Here, we report the use of human epidermal growth factor receptor 2 (HER2) 225 Ac-pretargeted radioimmunotherapy (PRIT) to treat a mouse model of human EOC SKOV3 xenografts growing as peritoneal carcinomatosis (PC). Methods: On day 0, 10 5 SKOV3 cells transduced with a luciferase reporter gene were implanted intraperitoneally in nude mice, and tumor engraftment was verified by bioluminescent imaging (BLI). On day 15, treatment was started using 1 or 2 cycles of 3-step anti-HER2 225 Ac-PRIT (37 kBq/cycle as 225 Ac- Proteus DOTA), separated by a 1-wk interval. Efficacy and toxicity were monitored for up to 154 d. Results: Untreated PC-tumor-bearing nude mice showed a median survival of 112 d. We used 2 independent measures of response to evaluate the efficacy of 225 Ac-PRIT. First, a greater proportion of the treated mice (9/10 1-cycle and 8/10 2-cycle; total, 17/20; 85%) survived long-term compared with controls (9/27, 33%), and significantly prolonged survival was documented (log-rank [Mantel-Cox] P = 0.0042). Second, using BLI, a significant difference in the integrated BLI signal area to 98 d was noted between controls and treated groups ( P = 0.0354). Of a total of 8 mice from the 2-cycle treatment group (74 kBq total) that were evaluated by necropsy, kidney radiotoxicity was mild and did not manifest itself clinically (normal serum blood urea nitrogen and creatinine). Dosimetry estimates (relative biological effectiveness-weighted dose, where relative biological effectiveness = 5) per 37 kBq administered for tumors and kidneys were 56.9 and 16.1 Gy, respectively. One-cycle and 2-cycle treatments were equally effective. With immunohistology, mild tubular changes attributable to α-toxicity were observed in both therapeutic groups. Conclusion: Treatment of EOC PC-tumor-bearing mice with anti-HER2 225 Ac-PRIT resulted in histologic cures and prolonged survival with minimal toxicity. Targeted α-therapy using the anti-HER2 225 Ac-PRIT system is a potential treatment for otherwise incurable EOC. (© 2023 by the Society of Nuclear Medicine and Molecular Imaging.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu